ClinicalTrials.gg
Active, not recruitingNCT04556773DB-08Updated Aug 3, 2026

A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer

A Phase 1 interventional study of Trastuzumab deruxtecan and Durvalumab in Metastatic Breast Cancer, sponsored by AstraZeneca. Active, not recruiting at 37 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
138
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms — 31 open to participants now, 45 under way, 8 of them phase 3. trastuzumab deruxtecan · Breast Neoplasms.

Enrollment
30th of 58
138 · median 139
Started
2020
with 8 others
Phase 1
6 of 58
1 open now
Primary completion
2023-08
later than 0 of 44 live
Registered
16th of 58
by date
Lead sponsor
9 of 58
AstraZeneca

Among the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, this one is the 30th largest by enrollment, is one of 9 that started in 2020, is one of 6 in phase 1, reaches primary completion later than 0 of the 44 other live ones, and was the 16th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

31 of the 58 studies testing trastuzumab deruxtecan in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

26 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About trastuzumab deruxtecan

trastuzumab deruxtecan: first FDA approval 2019 (ENHERTU), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies testing trastuzumab deruxtecan in Breast Neoplasms, or all of them as a file.
02

Study summary

DESTINY-Breast 08 will investigate the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other therapies in patients with Metastatic HER2-low Advanced or Metastatic Breast Cancer

Read the detailed description

This study is modular in design allowing assessment of the safety, tolerability, PK and preliminary anti-tumour activity of T-DXd in combination with other therapies. Combination-treatment modules will have 2 parts: a dose-finding phase (Part 1), and a dose expansion phase (Part 2); the Part 2 dose-expansion phase will use the RP2D determined in Part 1.

The target population of interest in this study is patients with HER2-low (IHC 1+ or IHC 2+/ISH -) (as per ASCO/CAP 2018 guidelines) advanced/MBC. Part 1 of each module will enroll patients with locally confirmed HER2-low advanced/MBC in second-line or later (≥ 2L) settings

Part 2 of each module will enroll patients with HER2-low MBC who have either not received prior treatment, or received only 1 prior treatment (depending on the module-specific exclusion criteria) for advanced/metastatic disease

03

Conditions studied

  • Metastatic Breast Cancer

Keywords

  • Breast Cancer
  • HER2-negative
  • HER2-low
  • Trastuzumab Deruxtecan
  • T-DXd
  • DS-8201a
  • DESTINY-Breast08
  • Anti-HER2 Antibody Drug Conjugate (ADC)
  • Triple-negative breast cancer (TNBC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patients must be at least 18 years of age
  • Male or female patients who have documented breast cancer that:

    1. Has a history of -low expression, defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested) with a validated assay
    2. Is documented as HR+ (either ER and/or PgR positive [ER or PgR ≥1%]) or ER and PgR negative (ER and PgR \<1%) per ASCO/CAP guidelines in the setting
  • Patient must have adequate tumor sample for biomarker assessment
  • Performance Status of 0 or 1

For patients with HR+ disease:

Part 1: At least 1 prior treatment line of ET with or without a targeted therapy (such as CDK4/6, mTOR or PI3-K inhibitors), and at least 1 for MBC are required.

Part 2: Only 1 prior treatment line of ET with or without a targeted therapy (such as CDK4/6, mTOR or PI3-K inhibitors) for MBC is allowed. No prior chemotherapy in the metastatic setting is allowed. Note there are no patients with HR+ disease in Part 2 of Modules 2 and 3.

For patients with HR- disease:

Part 1: At least 1 prior line of chemotherapy for MBC is required. Note there are no patients with HR- disease in Part 1 of Modules 4 and 5.

Part 2: For Module 2, no prior lines of therapy for MBC are allowed, and for Modules 1 and 3, only 1 prior line of chemotherapy for MBC is allowed. Note there are no patients with HR- disease in Part 2 of Modules 4 and 5.

Key Exclusion Criteria:

  • Uncontrolled intercurrent illness
  • Uncontrolled or siginificant cardiovascular disease
  • History of (non-infectious) ILD/pneumonitis that required , has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
  • Lung-specific intercurrent illnesses
  • Has spinal cord compression or clinically active central nervous system metastases
  • Active primary immunodeficiency
  • Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals
  • Prior treatment with ADC that comprises of an exatecan derivative that is a topoisomerase I inhibitor.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
138 participants (actual)

Study arms

  • Experimental
    Module 1: T-DXd + capecitabine

    T-DXd: 5.4 mg/kg Q3W, intravenous use Capecitabine: 1000mg/m2 BID, days 1-14 Q3W, oral use

    Drug: Trastuzumab deruxtecan · Drug: Capecitabine

  • Experimental
    Module 2: T-DXd + durvalumab + paclitaxel

    T-DXd: 5.4 mg/kg Q3W, intravenous use Durvalumab: 1120 mg Q3W, intravenous use Paclitaxel: 80 mg/m2 QW in 3-week cycles, intravenous use

    Drug: Trastuzumab deruxtecan · Drug: Durvalumab · Drug: Paclitaxel

  • Experimental
    Module 3: T-DXd + capivasertib

    T-DXd: 5.4 mg/kg Q3W, intravenous use Capivasertib: 400 mg BID, oral use

    Drug: Trastuzumab deruxtecan · Drug: Capivasertib

  • Experimental
    Module 4: T-DXd + anastrozole

    T-DXd: 5.4 mg/kg Q3W, intravenous use Anastrozole: 1 mg daily, oral

    Drug: Trastuzumab deruxtecan · Drug: Anastrozole

  • Experimental
    Module 5: T-DXd + fulvestrant

    T-DXd: 5.4 mg/kg Q3W, intravenous use Fulvestrant: 500 mg Q4W, intramuscular use

    Drug: Trastuzumab deruxtecan · Drug: Fulvestrant

Interventions

  • T-DXd: administered as an IV infusion

    Also known as: DS-8201a, T-DXd

  • Durvalumab: administered as an IV infusion

    Also known as: MEDI4736

  • Paclitaxel: administered as an IV infusion

    Also known as: Taxol A

  • Capivasertib: administered orally

    Also known as: AZD5363

  • Anastrozole: administered orally

    Also known as: Anastrozol

  • Fulvestrant: administered as an IM injection

  • Capecitabine: administered orally

06

What researchers measure

Primary outcomes

  1. Occurrence of adverse events (AEs)- Part 1

    Occurrence of AEs in Part 1 graded according to NCI CTCAE v5.0

    Time frame: Up to follow-up period, approximately 24 months

  2. Occurrence of serious adverse events (SAEs)- Part 1

    Occurrence of SAEs in Part 1 graded according to NCI CTCAE v5.0

    Time frame: Up to follow-up period, approximately 24 months

  3. Occurrence of adverse events (AEs)- Part 2

    Occurrence of AEs in Part 2 graded according to NCI CTCAE v5.0

    Time frame: Up to follow-up period, approximately 24 months

  4. Occurrence of serious adverse events (SAEs)- Part 2

    Occurrence of SAEs in Part 2 graded according to NCI CTCAE v5.0

    Time frame: Up to follow-up period, approximately 24 months

Secondary outcomes

  1. Objective Response Rate (ORR)- Part 2

    ORR defined as the proportion of patients who have a confirmed CR or PR, as determined by the investigator at local site per RECIST 1.1

    Time frame: Until progression, assessed up to approximately 24 months

  2. Progression Free Survival (PFS)- Part 2

    PFS defined as time from the date of first dose until the date of progression as determined by the investigator at local site per RECIST 1.1, or death due to any cause

    Time frame: Until progression or death, assessed up to approximately 24 months

  3. Duration of Response (DoR)- Part 2

    DoR defined as time from the date of first documented response (which is subsequently confirmed) until the date of documented progression or death in the absence of disease progression

    Time frame: Until progression or death, assessed up to approximately 24 months

  4. Overall Survival (OS)- Part 2

    OS defined as time from the date of first dose until the date of death by any cause

    Time frame: Until death, assessed up to approximately 24 months

  5. Serum concentration of T-DXd, total anti-HER2 antibody and MAAA-1181a

    Determination of trastuzumab deruxtecan concentration in serum at different time points after trastuzumab deruxtecan administration

    Time frame: While on study drug up to study completion, approximately 24 months

  6. Immunogenicity of trastuzumab deruxtecan

    Percentage of patients who develop ADA for trastuzumab deruxtecan

    Time frame: Up to follow-up period, approximately 24 months

  7. Serum Concentration of durvalumab

    Determination of durvalumab concentration in serum at different time points after administration

    Time frame: While on study drug up to study completion, approximately 24 months

  8. Immunogenicity of durvalumab

    Percentage of patients who develop ADAs for durvalumab

    Time frame: Up to follow-up period, approximately 24 months

07

Study locations

37 sites
  • Research Site
    Commack, New York 11725, United States
  • Research Site
    Harrison, New York 10604, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    Uniondale, New York 11553, United States
  • Research Site
    Chapel Hill, North Carolina 27514, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Germantown, Tennessee 38138, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Melbourne, 3000, Australia
  • Research Site
    Westmead, 2145, Australia
  • Research Site
    Edegem, 2650, Belgium
  • Research Site
    Leuven, 3000, Belgium
  • Research Site
    Ottignies, 1340, Belgium
  • Research Site
    Goiânia, 74605-070, Brazil
  • Research Site
    Porto Alegre, 90035-003, Brazil
  • Research Site
    Porto Alegre, 90110-270, Brazil
  • Research Site
    São Paulo, 03102-002, Brazil
  • Research Site
    São Paulo, 04543-000, Brazil
  • Research Site
    Kelowna, British Columbia V1Y 5L3, Canada
  • Research Site
    Québec, Quebec G1J 1Z4, Canada
  • Research Site
    Villejuif, 94805, France
  • Research Site
    Monterrey, 64710, Mexico
  • Research Site
    Moscow, 115478, Russia
  • Research Site
    Moscow, 143442, Russia
  • Research Site
    Saint Petersburg, 199226, Russia
  • Research Site
    Seoul, 03080, South Korea
  • Research Site
    Seoul, 03722, South Korea
  • Research Site
    Seoul, 05505, South Korea
  • Research Site
    Seoul, 06351, South Korea
  • Research Site
    Kaohsiung City, 82445, Taiwan
  • Research Site
    Taichung, 40443, Taiwan
  • Research Site
    Taipei, 100, Taiwan
  • Research Site
    Taipei, 11217, Taiwan
  • Research Site
    Taipei, 114, Taiwan
  • Research Site
    Taipei, 235, Taiwan
  • Research Site
    Taoyuan, 333, Taiwan
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Aug 2023, 31 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 31 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2020
First posted
Sep 21, 2020
StartActual
Dec 17, 2020
Primary completionActual
Aug 16, 2023
CompletionEst.
Jun 1, 2027
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04556773
Lead sponsor
AstraZeneca
Collaborators
Daiichi Sankyo Co., Ltd., Daiichi Sankyo Company, Limited
Responsible party
Sponsor
First posted
Sep 21, 2020
Start date
Dec 17, 2020
Primary completion
Aug 16, 2023
Completion
Jun 1, 2027 (estimated)
Last update
Aug 3, 2026

Study contacts

Komal Jhaveri, MD, FACP
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab deruxtecan

Start the discussion